INmune Bio completes randomization of 208 patients in Phase 2 Alzheimer's trial; top-line data Q2 2025

Inmune Bio, Inc.

Total of 208 patients enrolled, exceeding target; 56% mild AD and 44% MCI.
Top-line cognitive results expected in Q2 2025 for the Phase 2 AD02 trial.
Trial uses XPro to target glial-driven neuroinflammation in early Alzheimer's.
Global, blinded, randomized Phase 2 trial; first doses administered to all patients.
CEO RJ Tesi cited overenrollment as a major accomplishment for the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.